1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- 1- Yl) Ureas as P38 Map Kinase Inhibitors
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/GB2012/052445, filed Oct 3, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,108,950 | 1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- 1- Yl) Ureas as P38 Map Kinase Inhibitors In force · High confidence | Respivert Limited | In force | High confidence | ||
| US 9,850,231 | 1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- I - Yl) Ureas as P38 Mapkinase Inhibitors In force · Low confidence | Respivert Limited | In force | Low confidence | ||
| US 10,266,519 | 1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- I - Yl) Ureas as P38 Mapkinase Inhibitors In force · Low confidence | Respivert Limited | In force | Low confidence | ||
| US 10,738,032 | 1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- I - Yl) Ureas as P38 Mapkinase Inhibitors In force · Low confidence | Respivert Limited | In force | Low confidence | ||
| Application 17/683,893 | 1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- I - Yl) Ureas as P38 Mapkinase Inhibitors Abandoned Abandoned Feb 7, 2023 | Respivert Limited | Abandoned | Abandoned Feb 7, 2023 | ||
| Application 17/937,932 | 1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- I - Yl) Ureas as P38 Mapkinase Inhibitors Abandoned Abandoned May 23, 2023 | Respivert Limited | Abandoned | Abandoned May 23, 2023 | ||
| Application 18/171,503 | 1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- I - Yl) Ureas as P38 Mapkinase Inhibitors Abandoned Abandoned Nov 28, 2023 | Respivert Limited | Abandoned | Abandoned Nov 28, 2023 | ||
| Application 18/355,710 | 1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- I - Yl) Ureas as P38 Mapkinase Inhibitors Abandoned Abandoned Sep 11, 2024 | Respivert Limited | Abandoned | Abandoned Sep 11, 2024 |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Respivert Limited.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.